| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
MCA targets proteases, particularly matrix metalloproteinases (MMPs) and related enzymes that cleave the specific peptide sequence in the substrate. The compound serves as a fluorogenic substrate for these enzymes, releasing the MCA fluorophore upon enzymatic cleavage.
|
|---|---|
| ln Vitro |
The in vitro activity of MCA is its function as a fluorogenic substrate for proteases. In the intact substrate, the fluorescence of the MCA group is quenched by the Dnp group through FRET. Upon enzymatic cleavage, the MCA and Dnp groups are separated, resulting in a significant increase in fluorescence that can be quantified.
|
| ln Vivo |
MCA is not used as a therapeutic agent. Its in vivo utility is limited to research applications involving the measurement of protease activity in biological samples. The compound is not intended for systemic therapeutic use.
|
| Enzyme Assay |
In vitro enzyme assays for MCA involve incubating the fluorogenic substrate with protease enzyme preparations in appropriate buffer conditions. The enzyme cleaves the substrate, separating the MCA and Dnp groups and resulting in increased fluorescence. The fluorescence intensity is proportional to protease activity.
|
| Cell Assay |
For in vitro cellular experiments, MCA is typically used in cell-free systems for enzyme activity assays. The substrate can be added to cell lysates or purified enzyme preparations to assess protease activity. The fluorogenic readout provides a sensitive and quantitative measure of enzyme activity.
|
| Animal Protocol |
In vivo animal experiments with MCA are not typically performed, as the compound is used as an in vitro enzyme substrate. However, the substrate can be used to measure protease activity in samples collected from animal models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of MCA have not been characterized, as it is a research-use enzyme substrate rather than a drug candidate. The compound should be stored under appropriate conditions, protected from light.
|
| Toxicity/Toxicokinetics |
Toxicological data for MCA has not been systematically evaluated, as it is intended for research applications only and not for therapeutic use. Standard laboratory safety precautions should be observed.
|
| References |
|
| Additional Infomation |
7-Methoxycoumarin-4-acetic acid is a monocarboxylic acid that can be used as a fluorescent dye, and its function is similar to that of coumarins.
MCA is a fluorogenic substrate for matrix metalloproteinases and related proteases, utilizing FRET between MCA and Dnp groups for sensitive quantification of enzyme activity. The compound has no clinical or therapeutic applications. |
| Molecular Formula |
C12H10O5
|
|---|---|
| Molecular Weight |
234.20
|
| Exact Mass |
234.052
|
| CAS # |
62935-72-2
|
| Related CAS # |
(7-Methoxy-2-oxo-2H-chromen-4-yl)-acetic acid-d3;(7-Methoxy-2-oxo-2H-chromen-4-yl)-acetic acid-d6
|
| PubChem CID |
342221
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
472.9±45.0 °C at 760 mmHg
|
| Melting Point |
193 °C (dec.)(lit.)
|
| Flash Point |
189.2±22.2 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.584
|
| LogP |
1.52
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
17
|
| Complexity |
360
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC2=C(C=C1)C(=CC(=O)O2)CC(=O)O
|
| InChi Key |
ZEKAXIFHLIITGV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H10O5/c1-16-8-2-3-9-7(4-11(13)14)5-12(15)17-10(9)6-8/h2-3,5-6H,4H2,1H3,(H,13,14)
|
| Chemical Name |
2-(7-methoxy-2-oxochromen-4-yl)acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 25 mg/mL (106.75 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.67 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.67 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2699 mL | 21.3493 mL | 42.6985 mL | |
| 5 mM | 0.8540 mL | 4.2699 mL | 8.5397 mL | |
| 10 mM | 0.4270 mL | 2.1349 mL | 4.2699 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
